Literature DB >> 11050440

Reverse vaccinology.

R Rappuoli1.   

Abstract

Biochemical, serological and microbiological methods have been used to dissect pathogens and identify the components useful for vaccine development. Although successful in many cases, this approach is time-consuming and fails when the pathogens cannot be cultivated in vitro, or when the most abundant antigens are variable in sequence. Now genomic approaches allow prediction of all antigens, independent of their abundance and immunogenicity during infection, without the need to grow the pathogen in vitro. This allows vaccine development using non-conventional antigens and exploiting non-conventional arms of the immune system. Many vaccines impossible to develop so far will become a reality. Since the process of vaccine discovery starts in silico using the genetic information rather than the pathogen itself, this novel process can be named reverse vaccinology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11050440     DOI: 10.1016/s1369-5274(00)00119-3

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  198 in total

Review 1.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

2.  Identification of genes that contribute to the pathogenesis of invasive pneumococcal disease by in vivo transcriptomic analysis.

Authors:  Abiodun D Ogunniyi; Layla K Mahdi; Claudia Trappetti; Nadine Verhoeven; Daphne Mermans; Mark B Van der Hoek; Charles D Plumptre; James C Paton
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

3.  RNA interference screening in ticks for identification of protective antigens.

Authors:  José de la Fuente; Consuelo Almazán; Edmour F Blouin; Victoria Naranjo; Katherine M Kocan
Journal:  Parasitol Res       Date:  2005-04-12       Impact factor: 2.289

4.  A universal vaccine for serogroup B meningococcus.

Authors:  Marzia M Giuliani; Jeannette Adu-Bobie; Maurizio Comanducci; Beatrice Aricò; Silvana Savino; Laura Santini; Brunella Brunelli; Stefania Bambini; Alessia Biolchi; Barbara Capecchi; Elena Cartocci; Laura Ciucchi; Federica Di Marcello; Francesca Ferlicca; Barbara Galli; Enrico Luzzi; Vega Masignani; Davide Serruto; Daniele Veggi; Mario Contorni; Maurizio Morandi; Alessandro Bartalesi; Vanda Cinotti; Donatella Mannucci; Francesca Titta; Elisa Ovidi; Jo Anne Welsch; Dan Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-06       Impact factor: 11.205

5.  Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine.

Authors:  Peter T Beernink; Jo Anne Welsch; Lee H Harrison; Arunas Leipus; Sheldon L Kaplan; Dan M Granoff
Journal:  J Infect Dis       Date:  2007-04-05       Impact factor: 5.226

Review 6.  Patterns of antigenic diversity and the mechanisms that maintain them.

Authors:  Marc Lipsitch; Justin J O'Hagan
Journal:  J R Soc Interface       Date:  2007-10-22       Impact factor: 4.118

7.  Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1.

Authors:  Francesco Doro; Sabrina Liberatori; Manuel J Rodríguez-Ortega; Cira D Rinaudo; Roberto Rosini; Marirosa Mora; Maria Scarselli; Emrah Altindis; Romina D'Aurizio; Maria Stella; Immaculada Margarit; Domenico Maione; John L Telford; Nathalie Norais; Guido Grandi
Journal:  Mol Cell Proteomics       Date:  2009-04-28       Impact factor: 5.911

8.  Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Authors:  Susan Zolla-Pazner; Rebecca Powell; Sara Yahyaei; Constance Williams; Xunqing Jiang; Wei Li; Shan Lu; Shixia Wang; Chitra Upadhyay; Catarina E Hioe; Max Totrov; Xiangpeng Kong
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

Review 9.  Recent Trends in System-Scale Integrative Approaches for Discovering Protective Antigens Against Mycobacterial Pathogens.

Authors:  Aarti Rana; Shweta Thakur; Girish Kumar; Yusuf Akhter
Journal:  Front Genet       Date:  2018-11-27       Impact factor: 4.599

10.  Putative vaccine candidates and drug targets identified by reverse vaccinology and subtractive genomics approaches to control Haemophilus ducreyi, the causative agent of chancroid.

Authors:  Alissa de Sarom; Arun Kumar Jaiswal; Sandeep Tiwari; Letícia de Castro Oliveira; Debmalya Barh; Vasco Azevedo; Carlo Jose Oliveira; Siomar de Castro Soares
Journal:  J R Soc Interface       Date:  2018-05       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.